Why are tumour blood vessels abnormal and why is it important to know?
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Tumour blood vessels differ from their normal counterparts for reasons that have received little attention. We report here that they are of at least six distinct types, we describe how each forms, and, looking forward, encourage the targeting of tumour vessel subsets that have lost their vascular endothelial growth factor-A (VEGF-A) dependency and so are likely unresponsive to anti-VEGF-A therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although many in vitro microvessel models have been developed, none of them can actually reproduce the architecture of capillaries seen in a tumor [217,218].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [217]
Experimental — accuracy not yet measuredIn the citing paper
“The vasculature of tumors is very different from the blood vessels that supply healthy tissues, especially in terms of heterogeneity, permeability, multidirectional blood flow, and unordered distribution throughout the tumor160.”
From Tumor-on-a-chip: from bioinspired design to biomedical application (2021) · cites this paper as [160]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · cited 1×
“Furthermore, recent successes with agents that block VEGF-A or its receptors have supported Folkman’s (1971) thesis that anti-angiogenesis can be a useful supplement to traditional tumour therapy.”
BackgroundTumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“As was noted more than 20 years ago, tumour angiogenesis shares many analogies with wound healing (Dvorak, 1986).”
BackgroundSelf-citationTransplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis
Hellström, M., Phng, L.-K., Hofmann, J. J., Wallgard, E., Coultas, L., Lindblom, P., Alva, J., Nilsson, A.-K., Karlsson, L., Gaiano, N., et al. (2007) · Nature · doi:10.1038/nature05571 · Cited by 1,775 · cited 1×
“…of endothelial cells: non-dividing ‘tip’ cells at the leading edge that extend filopodia and sprouts in response to VEGF-A gradients and ‘stalk’ cells that follow behind, divide and exhibit reduced filopodia and sprouting because of signalling through the Notch/delta 4 axis (Hellstrom et al, 2007).”
BackgroundBergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370 · cited 1×
“…that anti-VEGF/VEGFR approaches have effectively treated mouse tumours at early stages of their development, but have proved to be less successful in treating established mouse tumours that contain large numbers of more mature, smooth muscle-cell-coated blood vessels (Bergers et al, 2003).”
BackgroundBergers, G., Song, S., Meyer-Morse, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317929 · Cited by 1,192
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039 · cited 2×
“Agents that neutralise VEGF (e.g., Avastin, VEGF-TRAP) or its receptors have provided proof of principle that anti-angiogenesis can be a useful adjunct to tumour therapy (Jain et al, 2006).”
BackgroundRuhrberg, C., Gerhardt, H., Golding, M., Watson, R., Ioannidou, S., Fujisawa, H., Betsholtz, C., & Shima, D. T. (2002) · Genes & Development · doi:10.1101/gad.242002 · Cited by 914 · cited 2×
“Mice engineered to express only VEGF-A120 develop to term but generate a capillary network with larger-sized vessels and fewer branch points (Ruhrberg et al, 2002).”
BackgroundLee, S., Jilani, S. M., Nikolova, G. V., Carpizo, D., & Iruela-Arispe, M. L. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200409115 · Cited by 703 · cited 2×
“Similar large, MV-like vessels can be generated by still smaller VEGF-As that result from matrix metalloprotease cleavage (Lee et al, 2005).”
BackgroundVasculogenic Mimicry and Tumor Angiogenesis
Folberg, R., Hendrix, M. J. C., & Maniotis, A. J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64739-6 · Cited by 684 · cited 1×
“…and DV result, respectively, from arteriogenesis and venogenesis. aIn addition, red blood-cell-filled spaces lined by tumour cells rather than by vascular endothelium have been described in some tumours, particularly ocular melanomas, and are referred to as ‘vascular mimicry’ (Folberg et al, 2000).”
Background
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
“Understanding VEGF Biology in Cancer VEGF secreted by tumor cells and surrounding stroma stimulates the proliferation and survival of endothelial cells, leading to the formation of new blood vessels, which may be structurally abnormal and leaky (Ferrara, 2010a, 2010b; Jain, 2003; Nagy et al., 2009).”
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
“Newly formed blood vessels typically occur in higher densities in tumor tissue [32,33], they often lack a smooth muscle layer and pericytes [34], they have a larger lumen and wider Golombek et al.”
BackgroundChallenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Chauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Nanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 981
Targeting the tumour vasculature: insights from physiological angiogenesis
Chung, A. S., Lee, J., & Ferrara, N. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2868 · Cited by 752
Developmental and Pathological Angiogenesis
Chung, A. S., & Ferrara, N. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154002 · Cited by 722
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 702
Colorectal cancer development and advances in screening
Balchen, V., & Simon, K. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s109285 · Cited by 665
“thus providing easy access to the lymph and circulatory systems and thereby promoting the spread of cancerous cells to distant organs.(10,18) Early detection and resection of precancerous polyps are critical to interrupt the adenomacarcinoma sequence and prevent the development and spread of CRC.”
Zimna, A., & Kurpisz, M. (2015) · BioMed Research International · doi:10.1155/2015/549412 · Cited by 604
“For instance, tumour vessels are leakier than normal vessels, and endothelial cells growing within tumours carry genetic abnormalities [20, 21].”
BackgroundPathological angiogenesis: mechanisms and therapeutic strategies
Dudley, A. C., & Griffioen, A. W. (2023) · Angiogenesis · doi:10.1007/s10456-023-09876-7 · Cited by 495
“However, it has become apparent that mature vessels may not require VEGF for survival; therefore, targeting VEGF is expected to have no ability to eliminate mature feeding vessels into solid tumors [369, 370].”
Biology and therapeutic targeting of vascular endothelial growth factor A
Pérez-Gutiérrez, L., & Ferrara, N. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00631-w · Cited by 484
“Numerous studies have described structural abnormalities associated with high leakiness, including reduced pericyte coverage, tortuosity (irregular twists and turns that reflect defective remodelling in vessels), microaneurisms, thinning of the endothelium and others 135,175,203 (Fig.”
BackgroundThe emerging role of photoacoustic imaging in clinical oncology
Lin, L., & Wang, L. V. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00615-3 · Cited by 469
The ever-expanding role of HIF in tumour and stromal biology
LaGory, E. L., & Giaccia, A. J. (2016) · Nature Cell Biology · doi:10.1038/ncb3330 · Cited by 430
Heterogeneity of the Tumor Vasculature
Nagy, J., Chang, S.-H., Shih, S.-C., Dvorak, A., & Dvorak, H. (2010) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0030-1253454 · Cited by 422
“6).(22,27,45,46) Arteriovenogenesis proceeds in parallel with angiogenesis, but almost nothing is known about the mechanisms involved.”
BackgroundSelf-citationThe eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation
Leprivier, G., Remke, M., Rotblat, B., Dubuc, A., Mateo, A.-R. F., Kool, M., Agnihotri, S., El-Naggar, A., Yu, B., Prakash Somasekharan, S., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.055 · Cited by 414
“Pathologic ND occurs along with hypoxia in early stages of tumor development before new blood vessels form or at later stages due to abnormal tumor vasculature (Nagy et al., 2009).”
Dudley, A. C. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006536 · Cited by 424
“Dvorak has nicely classified tumor vessels into six types based on their morphology (Nagy et al. 2009).”
BackgroundBioprinting for cancer research
Knowlton, S., Onal, S., Yu, C. H., Zhao, J. J., & Tasoglu, S. (2015) · Trends in Biotechnology · doi:10.1016/j.tibtech.2015.06.007 · Cited by 361
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Goel, S., Wong, A. H.-K., & Jain, R. K. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006486 · Cited by 352
“…abundance of VEGF and other proangiogenic factors drives 2 Cite this article as Cold Spring Harb Perspect Med 2012;2:a006486 w w w .p er sp ec ti ve si n m ed ic in e. o rg continual angiogenesis and the production of an abnormal blood vessel network (Jain 2005a; Nagy et al. 2009).”
BackgroundUnderstanding the tumor microenvironment for effective immunotherapy
Sadeghi Rad, H., Monkman, J., Warkiani, M. E., Ladwa, R., O'Byrne, K., Rezaei, N., & Kulasinghe, A. (2021) · Medicinal Research Reviews · doi:10.1002/med.21765 · Cited by 334
“Tumor cells that are able to grow rapidly often develop hypoxic regions that contribute to aberrant angiogenesis and thus disrupt lymphocyte infiltration.(178) This event is the result of abnormalities in the distribution, branching”
BackgroundChen, S., Zhong, Y., Fan, W., Xiang, J., Wang, G., Zhou, Q., Wang, J., Geng, Y., Sun, R., Zhang, Z., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00701-4 · Cited by 325
Targeting angiogenesis in oncology, ophthalmology and beyond
Cao, Y., Langer, R., & Ferrara, N. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00671-z · Cited by 315
Extracellular regulation of VEGF: Isoforms, proteolysis, and vascular patterning
Vempati, P., Popel, A. S., & Mac Gabhann, F. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.11.002 · Cited by 313
“Similar dysfunction is also found in retinopathy and neovascular macular degeneration [69,192] and controlling these excessively angiogenic states is currently a major therapeutic goal.”
BackgroundSpaide, R. F. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.04.012 · Cited by 313
Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
Taurin, S., Nehoff, H., & Greish, K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.07.013 · Cited by 309
Ceci, C., Atzori, M. G., Lacal, P. M., & Graziani, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041388 · Cited by 246
Tumor-on-a-chip: from bioinspired design to biomedical application
Liu, X., Fang, J., Huang, S., Wu, X., Xie, X., Wang, J., Liu, F., Zhang, M., Peng, Z., & Hu, N. (2021) · Microsystems & Nanoengineering · doi:10.1038/s41378-021-00277-8 · Cited by 246
Mansurov, A., Ishihara, J., Hosseinchi, P., Potin, L., Marchell, T. M., Ishihara, A., Williford, J.-M., Alpar, A. T., Raczy, M. M., Gray, L. T., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0549-2 · Cited by 235
CD133: beyond a cancer stem cell biomarker
Barzegar Behrooz, A., Syahir, A., & Ahmad, S. (2019) · Journal of Drug Targeting · doi:10.1080/1061186x.2018.1479756 · Cited by 235
“All of these vessels have several features in common, such as large size, hyperpermeable and pericyte-poor sinusoids [84].”
BackgroundMicrofluidic modelling of the tumor microenvironment for anti-cancer drug development
Shang, M., Soon, R. H., Lim, C. T., Khoo, B. L., & Han, J. (2019) · Lab on a Chip · doi:10.1039/c8lc00970h · Cited by 227
mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo
Rybakova, Y., Kowalski, P. S., Huang, Y., Gonzalez, J. T., Heartlein, M. W., DeRosa, F., Delcassian, D., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.012 · Cited by 218
“This phenomenon can lead to nanoparticle accumulation and retention (reviewed in Nagy et al.(47) and Kanasty et al.”
BackgroundThe Warburg metabolism fuels tumor metastasis
Lu, J. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09794-5 · Cited by 218
Molecular Mechanisms of Tumor Angiogenesis
Ziyad, S., & Iruela-Arispe, M. L. (2011) · Genes & Cancer · doi:10.1177/1947601911432334 · Cited by 215
Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy
Gupta, S., Roy, A., & Dwarakanath, B. S. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00068 · Cited by 218
“Metabolic Reprograming of CAFs As the vasculature within a solid tumor is considered to be larger and “abnormal” compared to their normal counterparts (25), they are considered to be comparatively less efficient.”
BackgroundSimultaneous measurement of RBC velocity, flux, hematocrit and shear rate in vascular networks
Kamoun, W. S., Chae, S.-S., Lacorre, D. A., Tyrrell, J. A., Mitre, M., Gillissen, M. A., Fukumura, D., Jain, R. K., & Munn, L. L. (2010) · Nature Methods · doi:10.1038/nmeth.1475 · Cited by 214
Breast cancer models: Engineering the tumor microenvironment
Bahcecioglu, G., Basara, G., Ellis, B. W., Ren, X., & Zorlutuna, P. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.02.006 · Cited by 213
“As a consequence, necrotic and low microvessel density regions may exist [124].”
BackgroundTrends and Challenges in Tumor Anti-Angiogenic Therapies
Jászai, J., & Schmidt, M. (2019) · Cells · doi:10.3390/cells8091102 · Cited by 208
“Moreover, VEGF dependence, maturation state, pericytic coverage, and the stromal (cytokine) microenvironment are all pivotal factors that crucially influence the accessibility and thus the success of the anti-angiogenic targeting of the heterogeneous vessel population embedded in the tumor stroma [45,225,229].”
BackgroundTargeting the tumour vasculature: from vessel destruction to promotion
Guelfi, S., Hodivala-Dilke, K., & Bergers, G. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00736-0 · Cited by 183
“In addition, interstitial pressure increases, and the resulting acidic, hypoxic tumour augments a pro-angiogenic feedback loop likening tumours to ‘wounds that never heal’ 23,24 .”
Targeted antibody and cytokine cancer immunotherapies through collagen affinity
Ishihara, J., Ishihara, A., Sasaki, K., Lee, S. S.-Y., Williford, J.-M., Yasui, M., Abe, H., Potin, L., Hosseinchi, P., Fukunaga, K., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau3259 · Cited by 190
Review of optical breast imaging and spectroscopy
Grosenick, D., Rinneberg, H., Cubeddu, R., & Taroni, P. (2016) · Journal of Biomedical Optics · doi:10.1117/1.jbo.21.9.091311 · Cited by 187
“In solid tumors, necrotic regions and regions of low microvessel density may occur, whereas tumor blood vessels are more abundant at the tumor–host interface.(14) Tumors may co-opt existing host vasculature for supply of oxygen and nutrients,(15,16) yet new vasculature must generally develop for tumors to grow beyond…”
BackgroundTumor microenvironment and progression
Dvorak, H. F., Weaver, V. M., Tlsty, T. D., & Bergers, G. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.21709 · Cited by 186
Self-citationDevelopmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1
Herkenne, S., Ek, O., Zamberlan, M., Pellattiero, A., Chergova, M., Chivite, I., Novotná, E., Rigoni, G., Fonseca, T. B., Samardzic, D., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.04.007 · Cited by 185
Vascular Endothelial Cells: Heterogeneity and Targeting Approaches
Hennigs, J. K., Matuszcak, C., Trepel, M., & Körbelin, J. (2021) · Cells · doi:10.3390/cells10102712 · Cited by 178
“classified the vascular network of the tumor into six vessel types according to their morphology: (1) mother vessels, which are enlarged, tortuous, thin-walled, pericyte-poor hyperpermeable sinusoids; (2) normal capillaries; (3) glomeruloid microvascular proliferations, which are tangles of tiny vessels immersed in a…”
BackgroundHuang, D., Sun, L., Huang, L., & Chen, Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020124 · Cited by 176
“2 μm in diameter) due to its lack of a smooth muscle layer and pericytes [7].”
BackgroundMechanical Forces in Tumor Angiogenesis
Zanotelli, M. R., & Reinhart-King, C. A. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-95294-9_6 · Cited by 153
Starvation and Pseudo-Starvation as Drivers of Cancer Metastasis through Translation Reprogramming
García-Jiménez, C., & Goding, C. R. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.11.018 · Cited by 150
“As tumors grow, the risk of both nutritional and hypoxic stress is enhanced by their frequently chaotic neovasculature (Nagy et al., 2009).”
BackgroundVascular normalisation as the stepping stone into tumour microenvironment transformation
Magnussen, A. L., & Mills, I. G. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01330-z · Cited by 146
Rodríguez-Enríquez, S., Carreño-Fuentes, L., Gallardo-Pérez, J. C., Saavedra, E., Quezada, H., Vega, A., Marín-Hernández, A., Olín-Sandoval, V., Torres-Márquez, M. E., & Moreno-Sánchez, R. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.07.010 · Cited by 142
The Fluid Mechanics of Cancer and Its Therapy
Koumoutsakos, P., Pivkin, I., & Milde, F. (2013) · Annual Review of Fluid Mechanics · doi:10.1146/annurev-fluid-120710-101102 · Cited by 129
“Furthermore, this therapy may damage only a subset of the tumor vessels and leave unaffected those that have acquired pericytes and smooth muscle cells (Nagy et al. 2009).”
BackgroundWilliford, J.-M., Ishihara, J., Ishihara, A., Mansurov, A., Hosseinchi, P., Marchell, T. M., Potin, L., Swartz, M. A., & Hubbell, J. A. (2019) · Science Advances · doi:10.1126/sciadv.aay1357 · Cited by 127
Glycosylation in the Tumor Microenvironment: Implications for Tumor Angiogenesis and Metastasis
Chandler, K. B., Costello, C. E., & Rahimi, N. (2019) · Cells · doi:10.3390/cells8060544 · Cited by 136
“In the tumor microenvironment (TME), dysregulation of angiogenic signals contributes to the development of hyper-permeable and highly heterogeneous blood vessels, and also aids in entry of tumor cells into (intravasation) and out of (extravasation) the blood stream via trans-endothelial migration [7].”
BackgroundMicrofluidic Organ-on-a-Chip System for Disease Modeling and Drug Development
Li, Z., Hui, J., Yang, P., & Mao, H. (2022) · Biosensors · doi:10.3390/bios12060370 · Cited by 120
Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment
Ito, K., Stannard, K. A., Gabutero, E., Clark, A. M., Neo, S., Onturk, S., Blanchard, H., & Ralph, S. J. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9388-2 · Cited by 148
Stress-mediated translational control in cancer cells
Leprivier, G., Rotblat, B., Khan, D., Jan, E., & Sorensen, P. H. B. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.11.002 · Cited by 146
Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation
Li, T., Mao, C., Wang, X., Shi, Y., & Tao, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01733-5 · Cited by 120
How does mTOR sense glucose starvation? AMPK is the usual suspect
Leprivier, G., & Rotblat, B. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0260-9 · Cited by 133
Molecular targeting of liposomal nanoparticles to tumor microenvironment
Zhao, G., & Rodriguez, L. B. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s37859 · Cited by 114
Ahmad, M. Z., Rizwanullah, M., Ahmad, J., Alasmary, M. Y., Akhter, M. H., Abdel‐Wahab, B. A., Warsi, M. H., & Haque, A. (2021) · International Journal of Polymeric Materials · doi:10.1080/00914037.2020.1869737 · Cited by 126
VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside
Arjaans, M., Schroder, C. P., Oosting, S. F., Dafni, U. G., Kleibeuker, J. E., & de Vries, E. G. E. (2016) · Oncotarget · doi:10.18632/oncotarget.6918 · Cited by 122
“The vascular organization and structure of tumors differs from normal tissue [10].”
WNT signaling – lung cancer is no exception
Rapp, J., Járomi, L., Kvell, K., Miskei, G., & Pongracz, J. E. (2017) · Respiratory Research · doi:10.1186/s12931-017-0650-6 · Cited by 120
“This is due to differential WNT expression induced modulation of cellular morphology and function leading even to cellular mimicry of cells in the resident vascular network [135, 136].”
BackgroundThe tumor microenvironment: shaping cancer progression and treatment response
Desai, S. A., Patel, V. P., Bhosle, K. P., Nagare, S. D., & Thombare, K. C. (2025) · Journal of Chemotherapy · doi:10.1080/1120009x.2023.2300224 · Cited by 106
“These anatomical abnormalities increase permeability, reduced blood flow, and impaired oxygen and food delivery to tumor cells [133].”
The Role of CC-Chemokines in the Regulation of Angiogenesis
Ridiandries, A., Tan, J. T. M., & Bursill, C. A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111856 · Cited by 114
Flow Rate Affects Nanoparticle Uptake into Endothelial Cells
Chen, Y. Y., Syed, A. M., MacMillan, P., Rocheleau, J. V., & Chan, W. C. W. (2020) · Advanced Materials · doi:10.1002/adma.201906274 · Cited by 110
Tumor Vascular Microenvironment Determines Responsiveness to Photodynamic Therapy
Maas, A. L., Carter, S. L., Wileyto, E. P., Miller, J. M., Yuan, M., Yu, G., Durham, A. C., & Busch, T. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3744 · Cited by 107
“setting wherein significant heterogeneity in tumor microenvironment, including its blood vessels, can exist (31, 32).”
Danewalia, S. S., & Singh, S. (2021) · Materials Today Bio · doi:10.1016/j.mtbio.2021.100100 · Cited by 119
Mason, R. P., Zhao, D., Liu, L., Trawick, M. L., & Pinney, K. G. (2011) · Integrative Biology · doi:10.1039/c0ib00135j · Cited by 104
Leung, M. C., Kievit, F. M., Florczyk, S. J., Veiseh, O., Wu, J. D., Park, J. O., & Zhang, M. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0198-3 · Cited by 110
“Extravascular pockets of bright red erythrocytes associated with poorly formed leaky vasculature, which is indicative of angiogenesis (33), were visible in Matrigel pre-cultured HepG2.”
Strategies for Delivering Nanoparticles across Tumor Blood Vessels
Sheth, V. M., Wang, L., Bhattacharya, R., Mukherjee, P., & Wilhelm, S. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202007363 · Cited by 110
Liu, S., Zhang, Y., Liu, Y., Wang, W., Gao, S., Yuan, W., Sun, Z., Liu, L., & Wang, C. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02076-y · Cited by 111
“Furthermore, as the main cytokine, VEGF effectively stimulates the pathological process, forming abnormal tumour blood vessels [97, 98].”
BackgroundA Microvascularized Tumor-mimetic Platform for Assessing Anti-cancer Drug Efficacy
Pradhan, S., Smith, A. M., Garson, C. J., Hassani, I., Seeto, W. J., Pant, K., Arnold, R. D., Prabhakarpandian, B., & Lipke, E. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-21075-9 · Cited by 96
Hypoxia-Induced Resistance to Chemotherapy in Cancer
Minassian, L. M., Cotechini, T., Huitema, E., & Graham, C. H. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12734-3_9 · Cited by 114
Drug radiotherapy combinations: Review of previous failures and reasons for future optimism
Higgins, G. S., O'Cathail, S. M., Muschel, R. J., & McKenna, W. G. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.012 · Cited by 107
“However, tumour blood vessels are typically functionally and anatomically abnormal and have a tortuous, hyperpermeable structure that results in increased interstitial fluid pressure as well as tumour hypoxia; markedly reducing the efficacy of radiotherapy [31,32].”
BackgroundCoaxial electrohydrodynamic atomization: Microparticles for drug delivery applications
Davoodi, P., Fěng, F., Xu, Q., Yan, W., Tong, Y. W., Srinivasan, M., Sharma, V. K., & Wang, C. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.004 · Cited by 95
Time course of the angiogenic response during normotrophic and hypertrophic scar formation in humans
van der Veer, W. M., Niessen, F. B., Ferreira, J. A., Zwiers, P. J., de Jong, E. H., Middelkoop, E., & Molema, G. (2011) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2011.00692.x · Cited by 95
“The variable VEGF mRNA expression and immunohistochemical staining in the epidermis of hypertrophic samples 12 weeks postoperatively (Figure 6) could be associated with increased expression of proinflammatory cytokines in HSs(1,25) or could represent local hypoxia, which can be a stimulus for the formation of aberrant…”
BackgroundBrain metastasization of breast cancer
Custódio-Santos, T., Videira, M., & Brito, M. A. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.03.004 · Cited by 107
“strategy utilized by tumour cells, the movement promoted by stromal cells, as well as by active mechanisms that attract cells to the vasculature, the induction of angiogenesis, and the effect of fluid shear stress on cell survival in circulation [65-67].”
BackgroundSystems biology of pro‐angiogenic therapies targeting the VEGF system
Gabhann, F. M., Qutub, A. A., Annex, B. H., & Popel, A. S. (2010) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.92 · Cited by 95
“In addition, VEGF delivery can result in hypervascular growth, or growth of abnormal vessels [70]; similar vessels are typically observed in tumors [67].”
BackgroundNeuropilins in the Context of Tumor Vasculature
Niland, S., & Eble, J. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030639 · Cited by 98
“Unlike healthy vasculature, the tumor vasculature is intrinsically leaky [310].”
BackgroundInfluentialYan, A., Joachims, M. L., Thompson, L. F., Miller, A. D., Canoll, P., & Bynoe, M. S. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.1118-18.2019 · Cited by 101
“Glomeruloid vessels are surrounded by multiple layers of basement membrane and are poorly perfused (Nagy et al., 2009).”
Background3D tumor angiogenesis models: recent advances and challenges
Bhat, S. M., Badiger, V. A., Vasishta, S., Chakraborty, J., Seetharam, P., Ghosh, S., & Joshi, M. B. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03814-0 · Cited by 95
Novel Oncologic Drugs: What They Do and How They Affect Images
Figueiras, R. G., Padhani, A. R., Goh, V., Vilanova, J. C., González, S. B., Martín, C. V., Gómez‐Caamaño, A., Naveira, A. B., & Choyke, P. L. (2011) · Radiographics · doi:10.1148/rg.317115108 · Cited by 85
“There are many different features of tumor vascularity (spatial heterogeneity and chaotic structure, high permeability to macromolecules, or heterogeneity of vascular density) that are characteristic of malignancy (45).”
Herst, P. M., Broadley, K. W. R., Harper, J. L., & McConnell, M. J. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.01.021 · Cited by 97
“Most solid tumors are supplied by a chaotic network of fragile and tortuous blood vessels, resulting in rapidly shifting patterns of hypoxia [34].”
BackgroundKim, J., Jung, S.-Y., Kwon, Y.-H., Lee, J., Lee, Y. M., Lee, B.-Y., & Kwon, S. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.19599 · Cited by 85
“During tumor progression, VEGF signaling is an important aspect of the tumor angiogenesis process because it closely related to the accelerated growth of tumors, invasion and metastasis, leading to the outgrowth of pathogenic vessels.(22) Similarly, VEGF signaling and monoclonal antibodies and small molecule inhibitor…”
BackgroundPassive targeting in nanomedicine: fundamental concepts, body interactions, and clinical potential
Narum, S. M., Le, T., Le, D. P., Lee, J. C., Donahue, N. D., Yang, W., & Wilhelm, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816662-8.00004-7 · Cited by 108
Physicochemical regulation of endothelial sprouting in a 3D microfluidic angiogenesis model
Verbridge, S. S., Chakrabarti, A., DelNero, P., Kwee, B., Varner, J. D., Stroock, A. D., & Fischbach, C. (2013) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.34587 · Cited by 82
Chloroquine and nanoparticle drug delivery: A promising combination
Pelt, J., Busatto, S., Mauro Ferrari, B., Thompson, E. A., Mody, K., & Wolfram, J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.007 · Cited by 93
“For example, tumors contain many irregularly branched tortuous blood vessels that lack pericytes, which are contractile cells that synthetize basal membrane and provide structural support for endothelial cells (Nagy et al., 2009).”
Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging
Moawad, A. W., Szklaruk, J., Lall, C. G., Blair, K. J., Kaseb, A. O., Kamath, A., Rohren, S., & Elsayes, K. M. (2020) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s224471 · Cited by 91
Chauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2020) · Nano-Enabled Medical Applications · doi:10.1201/9780429399039-10 · Cited by 81
Deciphering of cerebrovasculatures via ICG-assisted NIR-II fluorescence microscopy
Yu, X., Feng, Z., Cai, Z., Jiang, M., Xue, D., Zhu, L., Zhang, Y., Liu, J., Que, B., Yang, W., et al. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb01381d · Cited by 80
Yang, Y., Chien, M., Liu, H.-Y., Chang, Y., Chen, C.-K., Lee, W.-J., Kuo, T.-C., Hsiao, M., Hua, K., & Cheng, T. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.075 · Cited by 86
TGF-β signaling promotes tumor vasculature by enhancing the pericyte-endothelium association
Zonneville, J., Safina, A. F., Truskinovsky, A. M., Arteaga, C. L., & Bakin, A. V. (2018) · BMC Cancer · doi:10.1186/s12885-018-4587-z · Cited by 89
“Tumor blood vessels exhibit significant structural and functional abnormalities that provoke tumor hypoxia and metastatic spread [13].”
BackgroundTumour-vessel-on-a-chip models for drug delivery
Caballero, D., Blackburn, S. M., de Pablo, M., Samitier, J., & Albertazzi, L. (2017) · Lab on a Chip · doi:10.1039/c7lc00574a · Cited by 78
Chandler, K. B., Leon, D. R., Kuang, J., Meyer, R., Rahimi, N., & Costello, C. E. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.008643 · Cited by 86
Nel, A. E., Mei, K., Liao, Y., & Liu, X. (2022) · ACS Nano · doi:10.1021/acsnano.2c01252 · Cited by 84
Microfluidic lumen-based systems for advancing tubular organ modeling
Virumbrales-Muñoz, M., Ayuso, J. M., Gong, M. M., Humayun, M., Livingston, M. K., Lugo-Cintrón, K. M., McMinn, P., Álvarez-García, Y. R., & Beebe, D. J. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00705f · Cited by 76
Madar‐Balakirski, N., Tempel-Brami, C., Kalchenko, V., Brenner, O. J., Varon, D., Scherz, A. J., & Salomon, Y. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010282 · Cited by 75
“Reversed blood flow from the draining veins into the tumor was described earlier by others and said to reflect the impaired development of the tumor vasculature [10].”
BackgroundChang, W. H., Forde, D., & Lai, A. G. (2019) · 癌症:英文版 · doi:10.1186/s40880-019-0369-5 · Cited by 76
“Rapid neoplastic cell proliferation and overexpression of angiogenic factors leading to the formation of disorganized blood vessels result in insufficient oxygen supply to tumor cells [2, 3].”
BackgroundDvorak, H. F. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0039-1687908 · Cited by 78
Self-citation
Metadata
- Authors
- Nagy, J. A., Chang, S.-H., Dvorak, A. M., & Dvorak, H. F.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Dvorak, H F
- ORCID
- Nagy, J A
- Venue
- British Journal of Cancer
- Published
- 2009-02-24
- Volume
- 100
- Issue
- 6
- Pages
- 865-869
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2661770
- OpenAlex
- W2063556542
- Cited by
- 611
- References
- 38
- Citations by year
- 2026: 30 · 2025: 39 · 2024: 62 · 2023: 47 · 2022: 50 · 2021: 53 · 2020: 61 · 2019: 47 · 2018: 51 · 2017: 48 · 2016: 22 · 2015: 16 · 2014: 12 · 2013: 18 · 2012: 20
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Foundation for Cancer Research
- National Heart, Lung, and Blood Institute (R01HL064402, HL-64402)
- National Cancer Institute (P01 CA 92644, P01CA092644)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- tumor vasculature, VEGF-A, anti-VEGF therapy, tumor angiogenesis, anti-angiogenic therapy resistance
- MeSH terms
- Animals, Blood Vessels, Capillaries, Humans, Neoplasms, Neovascularization, Pathologic, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.